Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.56 |
| ▸ | CCR3 | P51677 | 20/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.56 |
| ▸ | CCR1 | P32246 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920220 | 0.91 | HRH1 (0.59) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL2918182 | 0.91 | HRH1 (0.59) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL2918173 | 0.91 | HRH1 (0.59) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL2923127 | 0.84 | HRH1 (0.66) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL6402560 | 0.83 | HRH1 (0.55) | HRH1CCR3KCNH2 | |
| SCHEMBL2922699 | 0.80 | HRH1 (0.58) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL2922547 | 0.79 | HRH1 (0.61) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL6649275 | 0.79 | HRH1 (0.61) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL1930931 | 0.78 | HRH1 (0.60) | HRH1CCR3KCNH2CCR1 | |
| SCHEMBL5986725 | 0.78 | HRH1 (0.60) | HRH1CCR3KCNH2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | HRH1 33/4885CCR3 2/4885KCNH2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.